At the 2020 European Academy of Dermatology and Venerology (EADV) Virtual Congress, data for 5-year efficacy and safety of tildrakizumab in adults with moderate-to-severe plaque psoriasis were presented across six posters. Overall, it was shown that tildrakizumab has a very favourable long-term efficacy and safety profile.
EMJ Dermatology 9 [Supplement 1] . 2021
February 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/06/Derm-Article-Dermatitis-Artefacta-Treatment-web-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/Mukherjee-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/jak-inhibitor-thumbnail2-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/04/Effect-of-Hemodialysis-on-Cutaneous-Manifestations-of-Chronic-Kidney-Disease-Thumbnail-940x564.png)